The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...
AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United StatesTherapy granted United States Food ...
Impella, which J&J touts as the world’s smallest heart pump, has a range of devices used for various heart conditions. Lexeo ...
Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025. Additional enrollment continues to advance across ...
Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted ...
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in ...
This month, VacZine Analytics, a specialist publisher in healthcare commercial analysis, releases a brand-new situation ...
When a house catches on fire, we assume that a smoke alarm inside will serve one purpose and one purpose only: warn the ...
News-Medical.Net on MSN
Neural pain pathways found to play crucial role in bone fracture healing
When a house catches on fire, we assume that a smoke alarm inside will serve one purpose and one purpose only: warn the ...
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback